201 related articles for article (PubMed ID: 33106475)
21. Characteristics of patients with major depressive disorder switching SSRI/SNRI therapy compared with those augmenting with an atypical antipsychotic in a real-world setting.
Kern DM; Cepeda MS; Castilla-Puentes RC; Savitz A; Etropolski M
Curr Med Res Opin; 2021 Aug; 37(8):1377-1384. PubMed ID: 33818238
[TBL] [Abstract][Full Text] [Related]
22. Efficacy outcomes from 3 clinical trials of edivoxetine as adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment.
Ball SG; Ferguson MB; Martinez JM; Pangallo BA; Nery ES; Dellva MA; Sparks J; Zhang Q; Liu P; Bangs M; Goldberger C
J Clin Psychiatry; 2016 May; 77(5):635-42. PubMed ID: 27035159
[TBL] [Abstract][Full Text] [Related]
23. Selective serotonin reuptake inhibitor and selective serotonin and norepinephrine reuptake inhibitor use and risk of fractures in adults: A systematic review and meta-analysis.
Khanassov V; Hu J; Reeves D; van Marwijk H
Int J Geriatr Psychiatry; 2018 Dec; 33(12):1688-1708. PubMed ID: 30247774
[TBL] [Abstract][Full Text] [Related]
24. Understanding the pharmacogenetics of selective serotonin reuptake inhibitors.
Fabbri C; Minarini A; Niitsu T; Serretti A
Expert Opin Drug Metab Toxicol; 2014 Aug; 10(8):1093-118. PubMed ID: 24930681
[TBL] [Abstract][Full Text] [Related]
25. Systems Approach to Identify Common Genes and Pathways Associated with Response to Selective Serotonin Reuptake Inhibitors and Major Depression Risk.
Srivastava A; Singh P; Gupta H; Kaur H; Kanojia N; Guin D; Sood M; Chadda RK; Yadav J; Vohora D; Saso L; Kukreti R
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31018568
[TBL] [Abstract][Full Text] [Related]
26. A pilot, open study of sertraline in outpatients with treatment-resistant depression (TRD) or with a history of TRD who responded but later relapsed.
Papakostas GI; Petersen T; Worthington JJ; Roffi PA; Alpert JE; Fava M; Nierenberg AA
Int Clin Psychopharmacol; 2003 Sep; 18(5):293-6. PubMed ID: 12920390
[TBL] [Abstract][Full Text] [Related]
27. Influence and interaction of genetic, cognitive, neuroendocrine and personalistic markers to antidepressant response in Chinese patients with major depression.
Bi Y; Ren D; Guo Z; Ma G; Xu F; Chen Z; An L; Zhang N; Ji L; Yuan F; Liu L; Hou B; Yang F; Yu S; Yi Z; Xu Y; He L; Sun X; Dong Z; Wu S; Zhao L; Cai C; Li X; Yu T; Shi Y; He G
Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jan; 104():110036. PubMed ID: 32702381
[TBL] [Abstract][Full Text] [Related]
28. Does adding noradrenaline reuptake inhibition to selective serotonin reuptake inhibition improve efficacy in patients with depression? A systematic review of meta-analyses and large randomised pragmatic trials.
Bradley AJ; Lenox-Smith AJ
J Psychopharmacol; 2013 Aug; 27(8):740-58. PubMed ID: 23832963
[TBL] [Abstract][Full Text] [Related]
29. A genome-wide association study of antidepressant response in Koreans.
Myung W; Kim J; Lim SW; Shim S; Won HH; Kim S; Kim S; Lee MS; Chang HS; Kim JW; Carroll BJ; Kim DK
Transl Psychiatry; 2015 Sep; 5(9):e633. PubMed ID: 26348319
[TBL] [Abstract][Full Text] [Related]
30. Higher polygenic risk scores for schizophrenia may be suggestive of treatment non-response in major depressive disorder.
Fanelli G; Benedetti F; Kasper S; Zohar J; Souery D; Montgomery S; Albani D; Forloni G; Ferentinos P; Rujescu D; Mendlewicz J; Serretti A; Fabbri C
Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jun; 108():110170. PubMed ID: 33181205
[TBL] [Abstract][Full Text] [Related]
31. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents.
Papakostas GI; Thase ME; Fava M; Nelson JC; Shelton RC
Biol Psychiatry; 2007 Dec; 62(11):1217-27. PubMed ID: 17588546
[TBL] [Abstract][Full Text] [Related]
32. An episode level evaluation of the treatment journey of patients with major depressive disorder and treatment-resistant depression.
Wu B; Cai Q; Sheehan JJ; Benson C; Connolly N; Alphs L
PLoS One; 2019; 14(8):e0220763. PubMed ID: 31393922
[TBL] [Abstract][Full Text] [Related]
33. What factors influence the prescribing of antidepressant pharmacotherapy? An assessment of national office-based encounters.
Sclar DA; Robison LM; Skaer TL; Galin RS
Int J Psychiatry Med; 1998; 28(4):407-19. PubMed ID: 10207740
[TBL] [Abstract][Full Text] [Related]
34. The humanistic and economic burden of treatment-resistant depression in Europe: a cross-sectional study.
Jaffe DH; Rive B; Denee TR
BMC Psychiatry; 2019 Aug; 19(1):247. PubMed ID: 31391065
[TBL] [Abstract][Full Text] [Related]
35. Polymorphism of rs3813034 in Serotonin Transporter Gene SLC6A4 Is Associated With the Selective Serotonin and Serotonin-Norepinephrine Reuptake Inhibitor Response in Depressive Disorder: Sequencing Analysis of SLC6A4.
Nonen S; Kato M; Takekita Y; Wakeno M; Sakai S; Serretti A; Kinoshita T
J Clin Psychopharmacol; 2016 Feb; 36(1):27-31. PubMed ID: 26674707
[TBL] [Abstract][Full Text] [Related]
36. Serotonin-norepinephrine reuptake inhibitor and selective serotonin reuptake inhibitor use and risk of fractures: a new-user cohort study among US adults aged 50 years and older.
Lanteigne A; Sheu YH; Stürmer T; Pate V; Azrael D; Swanson SA; Miller M
CNS Drugs; 2015 Mar; 29(3):245-52. PubMed ID: 25708711
[TBL] [Abstract][Full Text] [Related]
37. [Interest of the use of pindolol in the treatment of depression: review].
Brousse G; Schmitt A; Chereau I; Eschalier A; Dubray C; Llorca PM
Encephale; 2003; 29(4 Pt 1):338-50. PubMed ID: 14615704
[TBL] [Abstract][Full Text] [Related]
38. Long-Term, Open-Label, Safety Study of Edivoxetine 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment.
Ball SG; Atkinson S; Sparks J; Bangs M; Goldberger C; Dubé S
J Clin Psychopharmacol; 2015 Jun; 35(3):266-72. PubMed ID: 25815754
[TBL] [Abstract][Full Text] [Related]
39. [Efficacy of atypical antipsychotics in depressive syndromes].
Quintin P; Thomas P
Encephale; 2004; 30(6):583-9. PubMed ID: 15738862
[TBL] [Abstract][Full Text] [Related]
40. Whole blood transcriptional signatures associated with rapid antidepressant response to ketamine in patients with treatment resistant depression.
Cathomas F; Bevilacqua L; Ramakrishnan A; Kronman H; Costi S; Schneider M; Chan KL; Li L; Nestler EJ; Shen L; Charney DS; Russo SJ; Murrough JW
Transl Psychiatry; 2022 Jan; 12(1):12. PubMed ID: 35013133
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
